ANDA 214447, held by Alkem Laboratories. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 214447 (Methylphenidate Hydrochloride), held by Alkem Laboratories, was first approved by FDA on May 23, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2023 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride18MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride27MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride36MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride54MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters